Ammar Al-Chalabi
@ammaralchalabi.bsky.social
720 followers 740 following 35 posts
Professor of Neurology and Complex Disease Genetics, King's College London. Co-Director UK MND Research Institute https://ukmndri.org #MND #ALS Specialist. Deputy Editor, Brain
Posts Media Videos Starter Packs
Reposted by Ammar Al-Chalabi
longitudeprize.bsky.social
⏰ 2 months to go until applications close for the £7.5 million Longitude Prize on ALS.

You could help transform treatment for neurodegenerative diseases like hashtag #ALS, the most common form of motor neurone disease ( #MND ).

Learn more: bit.ly/4mlzSg5
Reposted by Ammar Al-Chalabi
end-the-legacy.bsky.social
Connect with us at #NealsMtg ! We are thrilled to be joining the NEALS meeting once again in person this coming week. For anyone impacted by ALS virtual registration is free. Cheers to NEALS for such an open policy. See more at https://meeting.neals.org/ . #EndtheLegacy #NEALS
ammaralchalabi.bsky.social
The biological evidence from changes in blood that the disease process starts years before symptoms matters for understanding risk factors and disease mechanisms. It is also important in clinic when people ask if an operation or injury caused their illness if in fact the process started years before
Reposted by Ammar Al-Chalabi
longitudeprize.bsky.social
🌍 Be part of the global effort to tackle #ALS.

The £7.5m (~$10m) #LongitudePrizeOnALS is searching for innovators in #AI, #data, #biotech, and #neurology.

🧠 Meet the teams already registered, and find out how you can partner with them below.

🔗https://bit.ly/4mdHxxX
Reposted by Ammar Al-Chalabi
longitudeprize.bsky.social
🧠 The @ukmndri.bsky.social is an #MND powerhouse, accelerating progress towards new treatments and, ultimately, a cure.

Read their article about how the #LongitudePrizeOnALS could be a game-changer for drug discovery in neurodegenerative diseases.

🔗 bit.ly/40Tmmsh

@ammaralchalabi.bsky.social
Longitude Prize launched to accelerate AI-driven drug discovery
A new international challenge prize has been launched to transform drug discovery for ALS, the most common form of MND through AI.
ukmndri.org
Reposted by Ammar Al-Chalabi
longitudeprize.bsky.social
“MND is one of the most scientifically and biologically challenging diseases to tackle. That said, no mountain is insurmountable…”

Dr. Mike Rogers (@mndassoc.bsky.social) shares why the #LongitudePrizeOnALS is key to creating new opportunities for #ALS & #MND

📰 longevity.technology/news/climbin...
Climbing the ALS mountain
Mike Rogers, MND Association Director of Research and Innovation, looks at how data and AI could unlock new treatments.
longevity.technology
Reposted by Ammar Al-Chalabi
smcgrath.phd
Tagging 🧪 🧬🖥️
scientificdiscovery.dev
Sad news:

The dataset behind this famous chart on the decline in costs of genome sequencing has had its NIH funding cut.

I loved this chart because it was the first that made me appreciate the impact of dataviz. But it also tracked progress towards an ambitious goal ($1000 genome) that succeeded.
NHGRI (at NIH)'s chart on the declining cost of sequencing a human genome from 2001 to 2021, falling faster than Moore's law. The "$1,000 genome" catchphrase was first publicly recorded in December 2001 at a scientific retreat to discuss the future of biomedical research following publication of the first draft of the Human Genome Project (HGP), convened by the National Human Genome Research Institute at Airlie House in Virginia.[5] The phrase neatly highlighted the chasm between the actual cost of the Human Genome Project, estimated at $2.7 billion over a decade, and the benchmark for routine, affordable personal genome sequencing.

On 2 October 2002, Craig Venter introduced the opening session of GSAC (The Genome Sequencing and Analysis Conference) at the Hynes Convention Center in Boston: "The Future of Sequencing: Advancing Towards the $1,000 Genome." Speakers included George M. Church and executives from 454 Life Sciences, Solexa, U.S. Genomics, VisiGen and Amersham plc.[6][7] In 2003, Venter announced that his foundation would earmark $500,000 for a breakthrough leading to the $1,000 genome.[8] That sum was subsequently rolled into the Archon X Prize.

In October 2004, NHGRI introduced the first in a series of '$1,000 Genome' grants designed to advance "the development of breakthrough technologies that will enable a human-sized genome to be sequenced for $1,000 or less."[9]
Reposted by Ammar Al-Chalabi
ukmndri.bsky.social
New research has examined how disrupted sleep patterns may signal the early stages of #MND / #ALS or FTD, providing clues to earlier detection.

Read more ⬇️
🔗 ukmndri.org/2025/07/16/r...

This post is part of our Research Snapshot series, powered by Readable Research at @sheffielduni.bsky.social
Could sleep changes signal the early stages of MND or FTD?
Research has found that disrupted sleep may offer some clues to possible early warning signs of the ALS or FTD.
ukmndri.org
Reposted by Ammar Al-Chalabi
longitudeprize.bsky.social
⏰ Reminder: Our first Welcome Webinar is tomorrow, Tuesday 9th of July at 09:00 BST.

💻 Register below to learn everything you need to know about the #LongitudePrizeOnALS, including how to apply, how the Prize works, and what support is available.
longitudeprize.bsky.social
Want to learn more about the £7.5M #LongitudePrizeOnALS?
Join one of our welcome webinars to find out how the Prize works and how to get involved.

Register here:
📅 9 July, 09:00 BST: bit.ly/4nzJuWA
📅 10 July, 17:00 BST: bit.ly/3Tl4u5u

#AIForGood #MND #ALS
Reposted by Ammar Al-Chalabi
longitudeprize.bsky.social
🧠 As the principal funder, the @mndassoc.bsky.social has been instrumental in bringing the #LongitudePrizeOnALS to life.

We were joined by Dr Usman Khan last week, who spoke on the power of cross-specialism collaboration.

Learn more about the Prize: bit.ly/4kD3tSh

#AIforGood #MND #ALS
Reposted by Ammar Al-Chalabi
longitudeprize.bsky.social
Want to learn more about the £7.5M #LongitudePrizeOnALS?
Join one of our welcome webinars to find out how the Prize works and how to get involved.

Register here:
📅 9 July, 09:00 BST: bit.ly/4nzJuWA
📅 10 July, 17:00 BST: bit.ly/3Tl4u5u

#AIForGood #MND #ALS
Reposted by Ammar Al-Chalabi
longitudeprize.bsky.social
Check out this article from Dr Brian Dickie (@mndassoc.bsky.social), exploring how #AI and quality data can transform treatment progress—and how the £7.5M #LongitudePrizeonALS aims to support #innovation through global collaboration.

🧠 Read here: bit.ly/4nqi4lN
#ALS #MND
Motor neurone disease affects one in 300, but hope for treatment is growing
One in 300 of us will develop motor neurone disease in our lifetime. It is a hideous disease that robs a person of their dignity and eventually their life.
bit.ly
Reposted by Ammar Al-Chalabi
ukmndri.bsky.social
Today is #MNDAwarenessDay, a moment to highlight the hidden realities of living with #MND.

Our translational research projects aim to find treatments for MND through a national, coordinated approach.

👉 Discover more: ukmndri.org/2025/06/20/f...
How our translational research will find new treatments for MND
On MND Awareness Day, we’re spotlighting the projects accelerating real progress and explaining why translational research is key.
ukmndri.org
Reposted by Ammar Al-Chalabi
kingscollegelondon.bsky.social
We are delighted to announce that Professor Sir Simon Wessely has been awarded a Knight Grand Cross of the Order of the British Empire (GBE) in this year's King’s 2025 Birthday Honours. 🎉 🧵⬇️

@kingsioppn.bsky.social
A dark blue quote card with King's logo and photo of Sir Simon. The quote reads: Being the first psychiatrist to receive this honour shows just how far mental health in general, and psychiatry in particular, has advanced since I started my psychiatry training at the Maudsley Hospital back in 1984. I was fortunate to then move to the Institute of Psychiatry in 1991, where I have been ever since. Whatever I have achieved since then would never have been possible without the support of both what is now the IoPPN and the wider King’s College London. But the most important thing of all has been the privilege to work with such generous, talented and extraordinary colleagues over all these years. My thanks to each and every one of you.”